These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29467940)

  • 1. ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models.
    Guo S; Zhang C; Bratton M; Mottamal M; Liu J; Ma P; Zheng S; Zhong Q; Yang L; Wiese TE; Wu Y; Ellis MJ; Matossian M; Burow ME; Miele L; Houtman R; Wang G
    Oncotarget; 2018 Jan; 9(6):6924-6937. PubMed ID: 29467940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD).
    Zhang C; Guo S; Yang L; Liu J; Zheng S; Zhong Q; Zhang Q; Wang G
    Oncotarget; 2017 Nov; 8(61):103874-103889. PubMed ID: 29262607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
    Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G
    Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).
    Liu J; Zheng S; Akerstrom VL; Yuan C; Ma Y; Zhong Q; Zhang C; Zhang Q; Guo S; Ma P; Skripnikova EV; Bratton MR; Pannuti A; Miele L; Wiese TE; Wang G
    J Med Chem; 2016 Sep; 59(17):8134-40. PubMed ID: 27529700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies.
    Liu J; Rajasekaran N; Hossain A; Zhang C; Guo S; Kang B; Jung H; Kim H; Wang G
    Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.
    Zhou F; Yang G; Xue L; Liu Y; Guo Y; Zhu J; Yuan L; Gu P; Tang F; Shan J; Tang R
    Breast Cancer Res; 2023 Aug; 25(1):96. PubMed ID: 37580832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.
    Shomali M; Cheng J; Sun F; Koundinya M; Guo Z; Hebert AT; McManus J; Levit MN; Hoffmann D; Courjaud A; Arrebola R; Cao H; Pollard J; Lee JS; Besret L; Caron A; Bangari DS; Abecassis PY; Schio L; El-Ahmad Y; Halley F; Tabart M; Certal V; Thompson F; McCort G; Filoche-Rommé B; Cheng H; Garcia-Echeverria C; Debussche L; Bouaboula M
    Mol Cancer Ther; 2021 Feb; 20(2):250-262. PubMed ID: 33310762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of a novel ZB716-d6 as a stable isotopically labeled internal standard.
    Zheng S; Liu J; Kang B; Wang G
    Synth Commun; 2022; 52(11-12):1441-1447. PubMed ID: 36420104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
    Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
    J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.
    Wardell SE; Marks JR; McDonnell DP
    Biochem Pharmacol; 2011 Jul; 82(2):122-30. PubMed ID: 21501600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
    Nagasawa J; Govek S; Kahraman M; Lai A; Bonnefous C; Douglas K; Sensintaffar J; Lu N; Lee K; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Joseph JD; Darimont B; Brigham D; Maheu K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2018 Sep; 61(17):7917-7928. PubMed ID: 30086626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
    Wardell SE; Yllanes AP; Chao CA; Bae Y; Andreano KJ; Desautels TK; Heetderks KA; Blitzer JT; Norris JD; McDonnell DP
    Breast Cancer Res Treat; 2020 Jan; 179(1):67-77. PubMed ID: 31562570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
    Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
    Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
    Tria GS; Abrams T; Baird J; Burks HE; Firestone B; Gaither LA; Hamann LG; He G; Kirby CA; Kim S; Lombardo F; Macchi KJ; McDonnell DP; Mishina Y; Norris JD; Nunez J; Springer C; Sun Y; Thomsen NM; Wang C; Wang J; Yu B; Tiong-Yip CL; Peukert S
    J Med Chem; 2018 Apr; 61(7):2837-2864. PubMed ID: 29562737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
    Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
    Wang L; Sharma A
    ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short chain fatty acids exhibit selective estrogen receptor downregulator (SERD) activity in breast cancer.
    Schoeller A; Karki K; Jayaraman A; Chapkin RS; Safe S
    Am J Cancer Res; 2022; 12(7):3422-3436. PubMed ID: 35968335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.